Lineage Cell Therapeutics (LCTX) EBIT Margin Growth (1y) (2011 - 2026)
Lineage Cell Therapeutics (LCTX) EBIT Margin Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -143.00 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 78.00 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1,049.00 |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1,238.00 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -10,520.00 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -1,651.00 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2,002.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 29,091.00 |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn | -11,933.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -11,933.00 |
| Mar 31, 2026 | -708.00 |
| Dec 31, 2025 | 7,908.00 |
| Sep 30, 2025 | -124.00 |
| Jun 30, 2025 | -29,868.00 |
| Mar 31, 2025 | 2,820.00 |
| Dec 31, 2024 | 12,652.00 |
| Sep 30, 2024 | 43,651.00 |
| Jun 30, 2024 | -26,091.00 |
| Mar 31, 2024 | -18,291.00 |
| Dec 31, 2023 | 4,199.00 |
| Sep 30, 2023 | -36,297.00 |
| Jun 30, 2023 | -6,279.00 |
| Mar 31, 2023 | -15,624.00 |
| Dec 31, 2022 | -29,021.00 |
| Sep 30, 2022 | 12,630.00 |
| Jun 30, 2022 | 128,982.00 |
| Mar 31, 2022 | 168,094.00 |
| Dec 31, 2021 | 160,043.00 |
| Sep 30, 2021 | 87,630.00 |